Repository corticotropin injection in patients with rheumatoid arthritis resistant to biologic therapies
| Autor: | Ronald J Rapoport, Peter A Fischer |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
rheumatoid arthritis
medicine.medical_specialty Disease Response Population 030204 cardiovascular system & hematology Research and Reviews [Open Access Rheumatology] 03 medical and health sciences 0302 clinical medicine Rheumatology Quality of life Prednisone Internal medicine biologic failure Clinical endpoint Medicine Disease Activity Score 28 using C-reactive protein (DAS28-CRP) melanocortin education Adverse effect Original Research 030203 arthritis & rheumatology Response rate (survey) education.field_of_study repository corticotropin injection business.industry refractory rheumatoid arthritis medicine.disease health-related quality of life Rheumatoid arthritis business medicine.drug |
| Zdroj: | Open Access Rheumatology : Research and Reviews |
| ISSN: | 1179-156X |
| Popis: | Peter A Fischer,1 Ronald J Rapoport2 1Sturdy Memorial Hospital, Attleboro, MA, USA; 2Division of Rheumatology, Southcoast Health, Fall River, MA, USA Introduction: Although synthetic and biologic disease-modifying antirheumatic drugs are available, many patients with rheumatoid arthritis have a difficult-to-control disease and need other treatment options. Repository corticotropin injection (RCI) may alleviate symptoms and exacerbations in patients with refractory disease. Methods: Nine patients with refractory rheumatoid arthritis were included in this study. Patients were maintained on their baseline therapies with a minimum of 7.5 mg prednisone daily. RCI was given daily at 40 U for 7 days. Patients who had an adequate disease response were given 40 U twice weekly through Week 12. For patients who had inadequate disease response, the dose was increased to 80 U daily for 7 days, followed by 80 U twice weekly through Week 12. Results: The primary endpoint was >1.2 point reduction in the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) at Week 12. Secondary endpoints were improvements in Health Assessment Questionnaire-Disease Index and Functional Assessment of Chronic Illness Therapy scores. Six of the nine patients met the primary endpoint. The average change in DAS28-CRP from baseline to Week 12 was numerically greater with 40 U than with 80 U RCI. Functional Assessment of Chronic Illness Therapy and Health Assessment Questionnaire-Disease Index improved as early as Week 1, and the improvements remained throughout treatment. Conclusion: There was no association between cortisol levels and low-dose RCI response. No serious adverse events occurred. RCI produced a clinically meaningful reduction in markers of disease activity, improved health-related quality of life, and a favorable safety profile. The response rate to RCI was substantial and shows promise in this difficult-to-treat population. Keywords: repository corticotropin injection, rheumatoid arthritis, Disease Activity Score 28 using C-reactive protein (DAS28-CRP), health-related quality of life, biologic failure, melanocortin, refractory rheumatoid arthritis |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|